Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

Investment Overview - Sanofi has made a strategic investment of $40 million in Vigil Neuroscience at an as-converted price of $7.44 per share of common stock, purchasing 537,634 Series A non-voting preferred shares convertible into common stock [6][7] - The investment is aimed at funding Vigil's research and development activities, particularly in the area of neurodegenerative diseases [6][2] Company Focus - Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring microglial function [3] - The company is developing precision-based therapies, including iluzanebart, a monoclonal antibody targeting TREM2 for a rare neurodegenerative disease, and VG-3927, a small molecule TREM2 agonist aimed at treating Alzheimer's disease [3][6] Strategic Implications - Sanofi's investment is seen as a validation of Vigil's precision medicine approach and strengthens Sanofi's commitment to immunoscience and neuroimmunology [2][6] - The proceeds from the investment are expected to extend Vigil's cash runway into 2026, allowing for continued development of its clinical programs [2][6]